Dr. Priya Jayachandran

Claim this profile

Los Angeles General Medical Center

Studies Breast Cancer
Studies Pancreatic Cancer
5 reported clinical trials
7 drugs studied

Area of expertise

1Breast Cancer
Priya Jayachandran has run 5 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
Stage IV
PR negative
2Pancreatic Cancer
Priya Jayachandran has run 2 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
HER2 negative
PR negative

Affiliated Hospitals

Image of trial facility.
USC / Norris Comprehensive Cancer Center
Image of trial facility.
Los Angeles General Medical Center

Clinical Trials Priya Jayachandran is currently running

Image of trial facility.

Sarilumab + Capecitabine

for Breast Cancer

This study looks to advance a novel and potent strategy to eliminate minimal residual disease (MRD) in triple negative breast cancer (TNBC) present even after multimodal treatment, thereby improving survival and increasing cure rate in this aggressive cancer. Patients with locally advanced TNBC are at high risk of developing lethal metastatic disease within 2 years of diagnosis, especially for those without a pathologic complete response (pCR) after neoadjuvant chemotherapy. The high risk occurs despite surgical excision of the primary tumor and axillary lymph nodes to eliminate residual disease.
Recruiting1 award Phase 1 & 212 criteria
Image of trial facility.

Carvedilol

for Preventing Heart Problems in HER2 Positive Breast Cancer

This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria

More about Priya Jayachandran

Clinical Trial Related12 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Priya Jayachandran has experience with
  • ARX788
  • Controlled Low Calorie Diet
  • Capecitabine
  • Sarilumab
  • Carvedilol
  • Trastuzumab Emtansine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Priya Jayachandran specialize in?
Is Priya Jayachandran currently recruiting for clinical trials?
Are there any treatments that Priya Jayachandran has studied deeply?
What is the best way to schedule an appointment with Priya Jayachandran?
What is the office address of Priya Jayachandran?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security